The process of drug development is expensive and time-consuming. In contrast, drug
repurposing can be introduced to clinical practice more quickly and at a reduced cost. Over …

Non-small cell lung cancer (NSCLC) overwhelmingly represents the predominant
histological subtype of lung cancer, with lung adenocarcinoma emerging as the most …

DNA is a key target for anticancer and antimicrobial drugs. Assessing the bioactivity of
compounds involves in silico and instrumental studies to determine their affinity for …

With the growing popularity of artificial intelligence in drug discovery, many deep-learning
technologies have been used to automatically predict unknown drug-target interactions …

The time-consuming and expensive nature of traditional drug discovery necessitates a cost-
effective approach to facilitate disease treatment. Drug repositioning, discovering innovative …

Cancer is one of the leading causes of mortality worldwide, highlighting the urgent need for
a deeper molecular understanding of the disease's heterogeneity and the development of …

Deoxynucleic acid (DNA) is one of the molecular targets against which anticancer and
antimicrobial drugs act. An important element in the assessment of the biological activity of …